In Cancer Care, Innovation Comes at a Cost
AJMC,
Cancer care is constantly evolving, with treatment armamentariums expanding and new data releases coming at an increasing pace.
PROTECT: Pazopanib falls short as adjuvant therapy for high-risk RCC
Pediatric News ,
CHICAGO – The antiangiogenic agent pazopanib is not efficacious when used as adjuvant therapy for resected renal cell carcinoma …
El pembrolizumab mejora por primera vez la supervivencia general al cáncer de riñón
National Cancer Institute,
2 de julio de 2024, por Carmen Phillips Algunas personas con cáncer de riñón extirpable corren un riesgo alto de que vuelva…
Pembrolizumab Achieves a First in Kidney Cancer
National Cancer Institute,
by Carmen Phillips Some people with kidney cancer that can be removed via surgery are at high risk of it coming back, including…